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Large-scale gene dose reductions usually lead to abnormal phenotypes or death. However, male mammals,
Drosophila, and Caenorhabditis elegans have only one X chromosome and thus can be considered as monosomic
for a major chromosome. Despite the deleterious effects brought about by such gene dose reduction in the case of
an autosome, X chromosome monosomy in males is natural and innocuous. This is because of the nearly full
transcriptional compensation for X chromosome genes in males, as opposed to no or partial transcriptional
compensation for autosomal one-dose genes arising due to deletions. Buffering, the passive absorption of
disturbance due to enzyme kinetics, and feedback responses triggered by expression change contribute to partial
compensation. Feed-forward mechanisms, which are active responses to genes being located on the X, rather than
actual gene dose are important contributors to full X chromosome compensation. In the last decade, high-
throughput techniques have provided us with the tools to effectively and quantitatively measure the small-fold
transcriptional effects of dose reduction. This is leading to a better understanding of compensatory mechanisms.
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Gene dose reductions are universal and have been stud-
ied in a variety of eukaryotes, including mammals [1-6],
birds [7], flies [8,9], worms [10], and yeasts [11]. It is
thought that gene dose reductions are tolerated or dele-
terious based on how out of balance the genome is fol-
lowing a dose change [12]. Although translation is the
closest direct measurement of levels of protein function
[13,14], which is what should count in the genic balance
hypothesis, transcription (mRNA abundance) is typically
measured. The importance of gene dose can be illus-
trated by co-expression levels of genes encoding proteins
that are part of the same multi-subunit complex [15].
This balance requirement may extend beyond genes en-
coding complex members. Although dose reductions of
only a few single genes are directly deleterious (haploin-
sufficient), the subtle effects of dose reduction for most
genes are cumulative and may eventually lead to the col-
lapse of the regulatory network. In flies, deletions reduce
viability when they reduce the gene dose for >1% of the
genome and cause death when they reduce the gene
dose for >3% of the genome [16]. This is not the result* Correspondence: zhen-xia.chen@nih.gov
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unless otherwise stated.of rare haploinsufficient loci scattered in the genome, as
large deletions are lethal even when smaller deletions
subdivided from them are viable. These data indicate
that the deleterious effects of most large deletions result
from the collapse of regulatory networks.
Natural monosomy of the X chromosome is a remark-
able exception to the rule of detrimental effects of large
gene dose imbalance. The viability of X chromosome
monosomies (i.e., males) is due to compensatory mecha-
nisms evolved to solve the genetic imbalances brought
by the emergence of sex chromosomes. Female mam-
mals and Drosophila have two X chromosomes, and
males have one X chromosome and one Y chromosome.
Hermaphrodite Caenorhabditis elegans have two X chro-
mosomes, and males have one X chromosome. While
still somewhat controversial, it appears that all three sys-
tems cope with monosomy by a twofold upregulation of
highly expressed X-linked genes in males to balance
gene expression between autosomes and sex chromo-
somes [17,18]. However, they have quite different stra-
tegies to balance female X chromosome expression in
the face of male dosage compensation [19]. In Drosoph-
ila, upregulation of X chromosome expression is limited
to males. In mammals, one X chromosome is globally
inactivated in females, while in C. elegans, both X chro-
mosomes in hermaphrodites are repressed by half [18].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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relative to autosomes is maintained in both sexes. X
chromosome dosage compensation is often stated as a
way to balance gene expression between the sexes, but it
is genic balance within a sex that must be rigorously
regulated.
Dosage compensation on autosomes and X chromosomes
One of the problems with thinking about X chromo-
some dosage compensation in males is our rudimentary
understanding of the relationship between gene dose
and expression when a non-sex chromosome suffers a
deletion. Effective measurements of minor-fold differ-
ence in expression are needed to track the response to
gene dose reduction on autosomes. We need to under-
stand this non-specialized response to dose in order to
determine if X chromosome dosage compensation is lay-
ered over a general response or if X chromosome dosage
compensation replaces a generic dosage compensation
system.
Cell lines and cancer cells are good models for stu-
dying the relationship between gene dose and ex-
pression, because they are selected for growth and
accumulate gene dose changes that would otherwise be
selected against in the organism [9,20]. In the absence of
compensation, genes with a 50% dose reduction would
have 50% of the expression. However, in Drosophila, par-
tial transcriptional compensation for dose reductions oc-
curs in some, but not all aneuploid cell lines [9,21].
Generally, as gene dose increases, the expression per
dose decreases and vice versa. Interestingly, gene dose
reduction seems to be marginally better compensated
than gene dose increase. For example, if there were no
compensation, the expression level of one-dose genes
and three-dose genes would be 50% and 150%, respec-
tively, of the diploid baseline; if there were full com-
pensation, their expression levels would both be 100%.
However, in the diploid D8 cell line, the expression level of
one-dose genes and three-dose genes are 75% and 133%,
respectively [9]. Interestingly, there are cell line-specific
differences in levels of compensation in Drosophila cell
lines. The cause of this variability is unknown, but it does
suggest that compensation is not a universal effect.
Perhaps, the levels of compensation are determined by the
selection against deleterious effects of imbalance, where
higher compensation would have evolved for more dele-
terious dose changes in these cells. Similarly, the higher
compensation for one-dose genes than that for three-dose
genes suggests that dose reduction is more deleterious to
cells than dose increase.
The genetic model organisms allow for careful moni-
toring of baseline dosage compensation responses. For
example, the DrosDel Deletion Collection has a set of
Drosophila melanogaster lines with mapped deletionstiling the genome in a common genetic background
[22]. Partial transcriptional compensation for one-dose
genes is also observed in these DrosDel lines. Microarray
analysis has found that the expression level of one-dose
genes is approximately 64% of the two-dose gene expres-
sion [23,24]. While there may be compression of expres-
sion ratios in array studies resulting in over-estimation of
compensation, and while the measurement of lowly
expressed genes are problematic in both array and RNA-
Seq experiments, the common trend is greater expression
than expected if the relationship between DNA dose and
RNA was 1:1. The consistent partial compensation ob-
served in different studies focused on different deletions
may be the result of a homogeneous dose response for all
one-dose genes in whole animals. This model is essentially
a dose damage response, where an unknown complex
mediating a fixed twofold increase in gene expression rec-
ognizes a deletion and applies a correction to gene expres-
sion. If this hypothesis is correct, we would expect a
normal distribution of expression change of one-dose
genes, as observed in one analysis [23]. While no mecha-
nism for a dose damage response is known, it may be
analogous to painting of fourth (POF). POF is a compen-
sation protein that decorates the very small (approxi-
mately 70 genes) chromosome 4 in Drosophila, which is
often lost resulting in monosomy [25]. The expression of
non-ubiquitously expressed genes on the fourth chromo-
some has been shown to be compensated by POF in flies,
and the lack of POF causes lethality, exactly as expected
for a dose damage response [23]. A competing model is
that observed levels of compensation are the result of the
characteristics of gene-specific dose responses. This is a
gene regulation or transcriptional homeostasis model. If
this hypothesis is correct, we would expect the dose
response is not uniform across genes, as observed in
the extended tails towards better compensation in the
distribution of expression change of one-dose genes
in one analysis [24]. Moreover, if the dose response
is heterogeneous, the genetic pathways including the
gene with altered gene dose should influence compensa-
tion. The consequences of incomplete or absent dosage
compensation are reduced expression of the one-dose
genes [17,21,24,26,27] and indirect propagating effects on
two-dose genes through regulatory networks [24,27-30].
Twenty-one different lines of Drosophila, each with
unique small deletions collectively covering 5% of genes,
resulted in the expression change in 80% of genes in the
entire genome [24]. In other words, the effect of a dose
change is not restricted to the genes with reduced copy.
There is extensive propagation of dose effects into the en-
tire gene expression network. The fact that compensation
for dose change in some aneuploid cells is stronger than
in adult Drosophila with deletions and that other aneu-
ploid cell lines show very poor compensation also argues
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much work that remains to be done on exploring the re-
sponse to gene dose, but these early studies suggest a way
towards developing better compensation models. We can
exploit current gene expression profiling models, but we
need to examine more genes to see if there are gene-
specific or region-specific compensation rules, determine
the nature of variable compensation responses, and map
out the propagation pathways to determine if they repre-
sent coherent biological pathways.
Although there is partial compensation for gene dose
reduction on the autosomes, full compensation for X
chromosome dose is observed in males. To solve the
genetic imbalances brought by the dose reduction of
X-linked genes, dosage compensation machinery needs
to recognize the X chromosome (targeting), increase ex-
pression of X-linked genes in males (upregulation), and
avoid the over-expression of the X chromosome genes in
females (restriction). In Drosophila, the MSL complex is
a male-specific ribonucleoprotein consisting of at least
five proteins male-specific lethal 1–3 (MSL1, MSL2, and
MSL3), maleless (MLE), and males absent on the first
(MOF) and two non-coding RNAs (RNA on the X (roX)
1 and 2). MSL1, MSL2, roX1, and roX2 are required for
targeting the X chromosome [31]. The roX1 and roX2
loci encode non-coding RNAs that are required for the
full assembly of MSL complex, as without roX RNAs,
MSL complex mis-localizes to centromeric heterochro-
matin [32]. The roX genes are X-linked, but when they
are translocated to autosomes, high-level expression of
roX genes still favors recruitment of MSL complex to
the X chromosome [32]. However, low-level expression
of autosomal roX genes favors local bidirectional spread-
ing of MSL complex, suggesting that roX RNAs are
incorporated into the MSL complex when they are tran-
scribed [33]. It is possible that X linkage is favorable forFigure 1 Mechanisms resulting in dosage compensation. (A) Buffering
to system properties such as kinetics. This does not result in full compensatio
generation and detection of an error in expression followed by intervention t
dosage compensation, results in the upregulation of all X chromosome generoX function. MOF, a histone acetyltransferase that
modifies histone H4 at lysine 16 (H4K16), performs the
upregulation function. H4K16 acetylation not only acti-
vates transcription [34] but also loosens chromatin
structure globally [35] and thus is considered to de-
repress X chromosome genes in males. An alternative,
less well-accepted model suggests that MOF is a global
activator of transcription [36] and that the MSL complex
sequesters MOF to the X chromosome to prevent the
upregulation of autosomal genes [37]. MOF does bind to
autosomal sites in both sexes [38], raising the possibility
that male-specific MSL complexes and non-sex-specific
MOF complexes exist and compete. Both the recruit-
ment of activator and sequestration models balance X
and autosome expression in both sexes. Sex-specific
regulation of MSL2 is also required to restrict MSL ac-
tion to males. The translation of msl2 mRNA is inhibited
by Sex-lethal (SXL), which responds to X chromosome
number resulting in SXL expression and dosage com-
pensation suppression only in females [39]. Since MSL
complex does not locate to the X chromosome without
MSL2, this ensures that upregulation of X chromosome
genes is limited to males.
Autosomal and X chromosome dosage compensation
may be mediated by one or more mechanisms, including
buffering, feedback, and feed-forward that can be used to
ameliorate the effect of gene dose reduction in living sys-
tems [21]. Buffering is the passive absorption of effects
caused by dose reduction. For example, gene transcription
may be considered as a chemical reaction obeying mass
action kinetics, where the template gene is a catalyst and
mRNAs are products. The flux (expression level) through
the reaction is dependent on kinetic parameters and
should not follow a linear relationship (Figure 1A) [40].
Therefore, the 50% dose reduction from two doses to one
dose should reduce expression <50% and thus result inresults in non-linear relationship between gene dose and expression due
n but can dampen the effect of gene dose. (B) Feedback requires the
o correct the error. (C) Feed-forward, as it relates to X chromosome
s regardless of the expression level.
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only lower the expression change caused by dose reduction,
but not eliminate it. At least some genes are overexpressed
as a result of decreased gene dose, which cannot be ex-
plained by buffering [24]. Feedback is an action triggered
by the expression change to restore the balance. For ex-
ample, the dose reduction of gene A leads to its expres-
sion reduction, which recruits regulator B to activate gene
A and thus demonstrate compensation (Figure 1B). Feed-
back, as error-controlled regulation, takes action when the
expression changes and thus can respond to expression
change caused by any disturbance. Moreover, the effect of
feedback is gene specific and may result in over-, full, par-
tial, no, or anti-compensation. Considering the hetero-
geneous dose response for most dose reductions [24],
feedback is likely to play an important role in partial com-
pensation. However, feedback might not be sufficient to
cope with the large number of dose changes due to mono-
somy of the X chromosome. Feed-forward is another ac-
tion to restore the gene expression with reduced dose. For
example, the regulator B may recognize and target the
one-dose gene A and suppress A's expression change be-
fore the fact (Figure 1C). Feed-forward anticipates the
dose reduction before it influences expression change and
thus may be crucial for full compensation; unlike in the
case of feedback, the correction occurs before the ex-
pression error is generated. Outside of the well-studied
MSL-mediated feed-forward system, we have a very poor
understanding of the contributions these mechanisms
make to X chromosome compensation. Indeed, there may
even be undiscovered feed-forward mechanisms to ex-
plain the MSL-independent full X chromosome com-
pensation in the Drosophila male germline for example
[17,18]. We do not understand how such feed-forward
themes evolved, but MSL components such as MOF are
widely deployed in other species as general activators of
transcription, suggesting that such general regulators
can be co-opted for chromosome-wide duties.
Why is X chromosome dosage compensation better than
autosomal compensation?
Full compensation, as observed for the Drosophila X
chromosome, is an elegant solution evolved to eliminate
the deleterious effects of dose reduction and genic imbal-
ance, and is clearly important for male viability. If dosage
compensation is so valuable, then full compensation for
deletions should also be favored. Why is compensation for
deletions so poor? In at least some situations, gene dose is
regulated in order to produce large amounts of product.
For example, there is differential amplification of genes in
terminally differentiated Drosophila cell, such as those
encoding eggshell proteins [41]. Full dosage compensation
would undo these advantageous dose differences. This is
not restricted to Drosophila. A high rate of aneuploidy,including dose reduction, appears to be part of normal
hepatocyte function in the mammalian liver [42]. Imprint-
ing can be viewed as an epigenetic dose reduction and is
widespread in many species [43]. Finally, there are a few X
chromosome genes that escape dosage compensation [43].
Given the multiple cases of regulated dose differences, it
seems likely that universal and full compensation would
be selected against.
One of the main differences between a sex chromosome
and autosomal monosomy is the long path to compensa-
tion in the X chromosome lineage. Deletions and auto-
somal monosomies are sporadic and generally have a very
short duration in the gene pool of any given species, while
sex chromosome evolution is a driven process that persists
in related species over many millions of years. It is pos-
sible that only sex chromosomes are fully compensated
because it takes a great deal of time to fully fine-tune the
process. For example, in Drosophila miranda, there are
three X chromosome fragments of differing age as a result
of interchromosome fusions: XL (>60 million years old),
XR (approximately 15 million years old), and neo-X
(approximately 1 million years old). Only partial com-
pensation is observed on the neo-X segment even though
the MSL machinery that already evolved to control X
chromosome compensation is co-opted to regulate the
neo-X segment [44,45]. It seems likely that new cis-acting
elements are acquired step by step over time, rather than
all at once [46].
Sexual selection might also be important for the evolu-
tion of X chromosome dosage compensation. To this
point, we have used sex chromosome dosage compensa-
tion as an example of full compensation; however, this is
not always the case. These exceptions might be quite
informative. In birds, which have ZW sex determination
(ZW females and ZZ males), only partial Z chromosome
dosage compensation is detected [47]. This partial com-
pensation might be similar to the autosomal compensa-
tion observed in Drosophila. The ZW sex determination
system dates to the dinosaurs, so we cannot explain the
lack of robust compensation by the absence of fine-tuning
time. We also cannot explain poor Z chromosome com-
pensation based on the fraction of the genome linked to
sex chromosomes. In Gallus gallus, the Z chromosome
comprises 8% of the genome [16,48-52], while reduced
dose for 3% of the fly genome cause death [16]. If the
number of genes on the Z cannot explain poor compensa-
tion, perhaps Z had a longer time to adapt due to the pe-
culiar nature of sex linkage, sexual selection, and mutation
rate [53].
Sexually antagonistic genes, which are advantageous to
one sex but deleterious to the other sex, will accumulate
to improve the function of one sex with the cost of redu-
cing function in the other sex. In XY systems, this results
in some predictions. Sexually antagonistic genes that are
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determinant on the proto-Y so that they can exert their
advantageous functions in males (with proto-Y) while
avoiding their deleterious functions in females (without
proto-Y). With the accumulation of sexually antagonistic
genes, the non-recombining region between proto-X and
proto-Y expanded, and eventually, the recombination bet-
ween sex chromosomes is suppressed in males but not in
females [54]. The absence of recombination between
proto-X and proto-Y led to the gradual degeneration of
the Y chromosome by accumulation of deleterious muta-
tions in an irreversible manner (called Muller's ratchet) or
through hitchhiking by favorable mutations (called selec-
tive sweeps) [55]. First, the loss of genes on proto-Y
chromosome may act as common dose reduction and be
compensated through buffering and feedback in a gene-
by-gene manner as the partial compensation. Later, with
the degeneration of proto-Y chromosome, the number of
one-dose X-linked genes increased in males [25]. In this
situation, the deleterious effect of dose reduction without
full compensation is large and unavoidable, and thus an
active response prior to the expression change rather than
a reaction to expression change is required. In this
scenario, feed-forward is strongly selected for in order to
restore the expression balance between autosomes and
X chromosome as well as between sexes. Instead of
responding to the expression change caused by dose re-
duction, this system responds a priori in the sex where
the X chromosome dose is expected to be one [21]. This
chromosome-wide upregulation may be achieved by a
combination of partial compensation and feed-forward
mechanisms [21,36], but how these mechanisms might
interact is unclear.
While in both XY and ZW systems the sex chromo-
somes arose from an ancestral autosome pair and genes
became lost on the Y and W chromosomes due to the
absence of recombination with a homolog, the two dif-
ferent systems might have required different dosage com-
pensation solutions. For example, in the bird population,
no W chromosomes are in males, while in Drosophila
populations, no Y chromosomes are in females. Thus, un-
like the autosomes, the sex chromosomes are not under
selection equally in the sexes. Both XY and ZZ males
should accumulate mutations faster due to the greater
number of cell divisions leading to spermatogenesis
relative to oogenesis. Considering the strong male-biased
mutation rate, if W-linked genes degenerate slower than
Y-linked genes, then the X chromosome would face a
greater dose imbalance due to faster Y chromosome gene
loss, thus leading to the evolution of full compensation in
XY systems and a more adaptive gene regulation response
in ZW systems, such as birds [47]. In this model, the par-
tial dosage compensation observed in birds would share
many of the gene-by-gene features of autosomal dosagecompensation in Drosophila. It would be interesting to de-
termine the differences between Z chromosome and auto-
some dosage compensation in these species.
Conclusions
There is full compensation for the one-dose X-linked
genes in males, while there is generally only partial com-
pensation for one-dose genes on the autosomes of either
sex. Buffering and feedback mechanisms may underlie the
partial compensation, while a feed-forward mechanism is
involved in the full compensation of X-linked genes in
wild-type males. This hypothesis is supported by evidence
from Drosophila, the most well-studied model for dosage
compensation. However, there are many unsolved ques-
tions: What is the exact contribution of each mechanism
to full compensation? What is the MSL-independent feed-
forward mechanism? How does the MSL complex achieve
twofold upregulation? etc. It is crucial to untangle com-
pensatory mechanisms and separate potential impacting
factors. For example, most systematic studies for dose
response focus on autosomal genes. It is still not clear
whether genes on different genomic location would have
different dose response. A systematic comparison between
the responses of one-dose X-linked genes and one-dose
autosomal genes in homogametic sex will provide us with
deeper understanding of compensatory mechanisms.
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